Background and study aims: Yearly surveillance endoscopy is carried out for Barrett’s esophagus with low-grade dysplasia (LGD) so that progression to high-grade dysplasia and adenocarcinoma can be detected at the earliest stage. The aim of the study was to assess the long-term safety and effectiveness of circumferential ablation followed by focal ablation (HALO system) for eliminating Barrett’s esophagus and LGD.
Patients and methods: Patients with 2 - 6 cm of Barrett’s esophagus with histology demonstrating LGD on their last two sequential endoscopies over the previous 2 years and confirmed by two pathologists were enrolled in this prospective, single-center trial. Circumferential ablation was carried out at baseline and at 4 months (if residual Barrett’s esophagus present). Endoscopy with 4-quadrant biopsies every 1 cm was performed at 1, 3, 6, 12, and 24 months. After 1 year, focal ablation was applied to any visible Barrett’s esophagus or irregularity of the squamocolumnar junction. Patients received lansoprazole 30 mg bid. Complete responses for dysplasia (CR-dysplasia) and intestinal metaplasia (CR-IM) at 2-year follow-up, with complete response defined as “all biopsies negative for dysplasia or intestinal metaplasia” were the main outcomes.
Results: Ten patients (nine men, mean age 66.9 years, range 48 - 79) with confirmed LGD (median 4.4 cm, range 3 - 6) underwent circumferential ablation with focal ablation after 1 year as necessary. At 2 years, CR-dysplasia was 100 % and CR-IM was 90 %. There were no strictures or buried intestinal metaplasia at follow-up.
Conclusion: A stepwise regimen of circumferential ablation followed by focal ablation appears to eradicate intestinal metaplasia (90 % CR-IM) and dysplasia (100 % CR-dysplasia) at 2-year follow-up in this trial, without stricture formation or buried intestinal metaplasia.
References
-
1
Shaheen N, Ransohoff D R.
Gastroesophageal reflux, Barrett’s esophagus and esophageal cancer.
JAMA.
2002;
287
1972-1981
-
2
Reid B J.
Barrett’s esophagus and adenocarcinoma.
Gastroenterol Clin North Am.
1991;
20
817-834
-
3
Peters J H, Hagen J A, DeMeester S R.
Barrett’s esophagus.
J Gastrointest Surg.
2004;
8
1-17
-
4
Sampliner R E.
Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus.
Am J Gastroenterol.
2002;
97
1888-1895
-
5
Sharma P, Falk G W, Weston A P. et al .
Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus.
Clin Gastroenterol Hepatol.
2006;
4
566-572
-
6
Odze R D.
Diagnosis and grading of dysplasia in Barrett’s oesophagus.
J Clin Pathol.
2006;
59
1029-1038
-
7
Sharma P.
Low-grade dysplasia in Barrett’s esophagus.
Gastroenterology.
2004;
127
1233-1238
-
8
Sharma P, McQuaid K, Dent J. et al .
A critical review of the diagnosis and management of Barrett’s esophagus - The AGA Chicago workshop.
Gastroenterology.
2004;
127
310-330
-
9
Sharma V K, Wang K K, Overholt B F. et al .
Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients.
Gastrointest Endosc.
2007;
65
185-195
-
10
Ganz R A, Utley D S, Stern R A. et al .
Complete ablation of esophageal epithelium with a balloon-based bipolar electrode: a phased evaluation in the porcine and in the human esophagus.
Gastrointest Endosc.
2004;
60
1002-1010
-
11
Dunkin B J, Martinez J, Bejarano P A. et al .
Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device (BÂRRX).
Surg Endosc.
2006;
20
125-130
-
12 Wolfsen H C, Utley D S, Peters J H. In: Yeo CJ, Dempsey DT, Klein AS et al. (eds). Shackelford’s surgery of the alimentary tract. 6th edn. Philadelphia; Saunders Elsevier 2007: 365-373
-
13
Smith C D, Bejarano P A, Melvin W S. et al .
Endoscopic ablation of intestinal metaplasia containing high-grade dysplasia in esophagectomy patients using a balloon-based ablation system.
Surg Endosc.
2007;
21
560-569
-
14
Dulai G S, Jensen D M, Cortina G. et al .
Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett’s esophagus.
Gastrointest Endosc.
2005;
61
232-240
-
15
Sampliner R E, Faigel D, Fennerty M B. et al .
Effective and safe endoscopic reversal of nondysplastic Barrett’s esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study.
Gastrointest Endosc.
2001;
53
554-558
-
16
Johnston M H, Eastone J A, Horwhat J D. et al .
Cryoablation of Barrett’s esophagus: a pilot study.
Gastrointest Endosc.
2005;
62
842-848
-
17
Gossner L, May A, Stolte M. et al .
KTP laser destruction of dysplasia and early cancer in columnarlined Barrett’s esophagus.
Gastrointest Endosc.
1999;
49
8-12
-
18
Seewald S, Akaraviputh T, Seitz U. et al .
Circumferential EMR and complete removal of Barrett’s epithelium: a new approach to management of Barrett’s esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma.
Gastrointest Endosc.
2003;
57
854-859
-
19
Overholt B F, Lightdale C J, Wang K K. et al .
Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial.
Gastrointest Endosc.
2005;
62
488-498
-
20
Shaheen N J, Dulai G S, Ascher B. et al .
Effect of a new diagnosis of Barrett’s esophagus on insurance status.
Am J Gastroenterol.
2005;
100
577-580
-
21
Shaheen N J, Green B, Medapalli R K. et al .
The perception of cancer risk in patients with prevalent Barrett’s esophagus enrolled in an endoscopic surveillance program.
Gastroenterology.
2005;
129
429-436
-
22
Shaheen N J, Crosby M A, Bozymski E M, Sandler R S.
Is there a publication bias in reporting cancer risk in Barrett’s esophagus?.
Gastroenterology.
2000;
119
333-338
-
23
Inadomi J M, Madanick R D, Somsouk M, Shaheen N J.
Radiofrequency ablation is more cost-effective than endoscopic surveillance or esophagectomy among patients with Barrett’s esophagus and low-grade dysplasia.
Gastroenterology.
2007;
132 Suppl S1
A-53
-
24
Sharma V K, Wells C, Kim H J. et al .
Successful ablation of Barrett esophagus with dysplasia using the HALO ablation system in a prospective cohort.
Am J Gastroenterol.
2007;
102 Suppl 2
S547
V. K. Sharma, MD
Division of Gastroenterology
Mayo Clinic in Arizona
13400 East Shea Blvd.
Scottsdale
AZ 85253
USA
Fax: +1-480-301-8673
Email: sharma.virender@mayo.edu